Source-grounded facts extracted from Solid Biosciences Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Solid Biosciences Inc. shareholders approved Non-binding advisory vote on compensation paid to named executive officers at the 2026-06-10 meeting.
“The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Solid Biosciences Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized common stock from 240,000,000 to 480,000,000 at the 2026-06-10 meeting.
“The Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 240,000,000 to 480,000,000 (the “Share Increase Amendment”).”
Solid Biosciences Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-10 meeting.
“The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Solid Biosciences Inc. shareholders approved Ratification of Ilan Ganot as a Class I director (advisory) at the 2026-06-10 meeting.
“The Company’s stockholders ratified the appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders.”
Solid Biosciences Inc. shareholders approved Election of Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors at the 2026-06-10 meeting.
“The Company’s stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders, each director to hold office until his or her successor has been duly appointed and qualified.”
Solid Biosciences Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025.
“Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company expects to report cash, cash equivalents and available-for-sale securities of approximately $187.9 million as of December 31, 2025.”
Solid Biosciences Inc. issued pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock of warrant to Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others for $5.609 per Pre-Funded Warrant.
“On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).”
Solid Biosciences Inc. issued 14,973,257 shares of the Company’s common stock of common stock to Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others for $5.61 per share.
“On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).”
Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $240.0 million (effective 2026-03-06).
“On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).”
Rajeev Shah resigned as Director at Solid Biosciences Inc..
“Rajeev Shah notified the Company of his decision to resign as a member of the Board, effective as of June 11, 2024.”
Adam Koppel resigned as Director at Solid Biosciences Inc..
“Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.”
Solid Biosciences Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.
“Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, the Company disclosed in the Presentation that it expects to report cash, cash equivalents and available-for-sale securities of approximately $123.9 million as of December 31, 2023.”
Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds from the Private Placement of approximately $108.9 million (effective 2024-01-08).
“On January 8, 2024, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 16,973,103 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.53 per share, and, to one Investor in lieu of Shares, pre-funded warrants to purchase 2,712,478 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.529 per Pre-Funded Warrant (the “ Private Placement ”).”
Solid Biosciences Inc. shareholders approved Amendment to the Company's 2021 Employee Stock Purchase Plan to increase number of shares available for issuance at the 2023-06-06 meeting.
“The Company’s stockholders approved an amendment to the Company’s 2021 Employee Stock Purchase Plan to increase the number of shares available for issuance thereunder.”
Solid Biosciences Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
“The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Solid Biosciences Inc. shareholders approved Election of Class II directors at the 2023-06-06 meeting.
“The Company held its Annual Meeting on June 6, 2023 to consider and vote upon the matters listed below.”
Jennifer Marlowe was appointed as Chief Scientific Officer at Solid Biosciences Inc..
“Following the Separation Date, Jennifer Marlowe, Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Pipeline of the Company, will assume Dr. Morris’ responsibilities and serve as Chief Scientific Officer of the Company.”
Carl Morris resigned as Chief Scientific Officer, Neuromuscular at Solid Biosciences Inc..
“On May 22, 2023, Solid Biosciences Inc. (the “Company”) and Carl Morris entered into an executive transition and separation agreement (the “Separation Agreement”) providing for Dr. Morris’ resignation as Chief Scientific Officer, Neuromuscular of the Company.”
Stephen DiPalma departed as Interim Chief Financial Officer at Solid Biosciences Inc..
“In connection with Mr. Tan’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer and principal financial officer and principal accounting officer, will cease to serve in such roles, effective as of the Appointment Date.”
Kevin Tan was appointed as Chief Financial Officer at Solid Biosciences Inc..
“On January 6, 2023, the Company’s Board of Directors (the “Board”) appointed Kevin Tan as the Company’s Chief Financial Officer, effective as of January 9, 2023”
Solid Biosciences Inc. announced a restructuring with charges of approximately $3.2 million (approximately 18%).
“On November 30, 2022, the Company’s Board of Directors (the “Board”) approved a plan to reduce the Company’s workforce by approximately 18%. These reductions are expected to be completed by the December 5, 2022. This plan is designed to streamline the Company’s operating structure. The Company expects to incur a charge in the fourth quarter of 2022 of approximately $3.2 million related to the reduction in force, consisting of severance and other employee termination benefits. The Company expects that approximately $0.4 million of this amount will be paid during in the fourth quarter of 2022 and the balance through the first quarter of 2024.”
Solid Biosciences Inc. completed an acquisition involving AavantiBio, Inc. (closed 2022-12-02).
“On December 2, 2022, the Company completed its acquisition of AavantiBio in accordance with the terms of the Merger Agreement.”
Solid Biosciences Inc. entered into a license with University of North Carolina valued at up to $5.0 million (effective 2021-12-21).
“On December 21, 2021, AavantiBio entered into an exclusive license agreement with the University of North Carolina (“UNC”) with respect to certain patent rights relating to truncated dysferlin for treatment of dysferlinopathy.”
Solid Biosciences Inc. entered into a license with Life Technologies Corporation valued at $450,000 upfront fee (effective 2020-12-18).
“On December 18, 2020, AavantiBio entered into a non-exclusive license agreement with Life Technologies Corporation, a Delaware corporation, with respect to life cells for producing genetically engineered adeno associated virus (AAV) particles.”
Solid Biosciences Inc. entered into UFRF License Agreements with University of Florida Research Foundation, Inc. valued at totaling up to $15.4 million.
“AavantiBio entered into multiple license agreements with the University of Florida Research Foundation, Inc. (the “UFRF License Agreements”).”
Erin Powers Brennan resigned as Chief Legal Officer and Secretary at Solid Biosciences Inc..
“Erin Powers Brennan notified the Company of her resignation as the Company’s Chief Legal Officer and Secretary”
Ilan Ganot resigned as Chief Executive Officer and President at Solid Biosciences Inc..
“Ilan Ganot notified the Company of his resignation as the Company’s Chief Executive Officer and President”
Adam Koppel was elected as Director at Solid Biosciences Inc..
“On November 30, 2022, the Board also elected Adam Koppel, M.D., Ph.D., as a member of the Board, subject to and contingent and effective upon the closing of the Acquisition.”
Alexander (Bo) Cumbo was appointed as President and Chief Executive Officer at Solid Biosciences Inc..
“On November 30, 2022, the Board appointed Alexander (Bo) Cumbo as the Company’s President and Chief Executive Officer and elected Mr. Cumbo as a member of the Board, in each case, subject to and contingent and effective upon the closing of the Acquisition (the “Effective Date”).”
Solid Biosciences Inc. shareholders approved To approve the adoption of the Amended and Restated 2020 Plan to increase the number of shares issuable thereunder.
“2. The Equity Incentive Plan Proposal . To consider and vote upon a proposal to approve the adoption of the Amended and Restated 2020 Plan to, among other things, increase the number of shares issuable thereunder. Votes For Votes Against Abstentions 3,480,064 614,534 8,406”
Solid Biosciences Inc. shareholders approved To approve issuance of shares pursuant to the Merger Agreement and Securities Purchase Agreements.
“1. The Share Issuance Proposal . To consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule 5635, the issuance of shares of the Company’s common stock pursuant to the terms of the Agreement and Plan of Merger, dated September 29, 2022, by and among the Company, Greenland Merger Sub LLC, AavantiBio and, solely in his capacity as equityholder representative, Doug Swirsky (the “Merger Agreement”) and the Securities Purchase Agreements, dated September 29, 2022, by and among the Company and several accredited investors named therein (the “Securities Purchase Agreement”) (such proposal, the “Share Issuance Proposal”). Votes For Votes Against Abstentions 4,054,470 41,480 7,054”
Alexander Cumbo was appointed as President and Chief Executive Officer at Solid Biosciences Inc..
“On September 29, 2022, the Company entered into an employment agreement with Alexander Cumbo (the “Cumbo Employment Agreement”), pursuant to which Mr. Cumbo will serve as the Company’s President and Chief Executive Officer, subject to his appointment to such position by the Board and subject to, and contingent and effective upon, the Effective Date.”
Erin Powers Brennan resigned as Chief Legal Officer and Secretary at Solid Biosciences Inc..
“On September 29, 2022, Erin Powers Brennan also notified the Company of her intention to resign as the Company’s Chief Legal Officer and Secretary, subject to, and contingent and effective upon, the Effective Date.”
Ilan Ganot resigned as Chief Executive Officer and President at Solid Biosciences Inc..
“On September 29, 2022, Ilan Ganot notified the Company of his intention to resign as the Company’s Chief Executive Officer and President, subject to, and contingent and effective upon, the closing of the Merger (such date, the “Effective Date”).”
Joel Schneider resigned as Chief Operating Officer at Solid Biosciences Inc..
“Joel Schneider, Chief Operating Officer of the Company, notified the Company of his intent to resign to accept a role as chief executive officer of a privately-held novel, viral-based gene therapy platform company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.